Associate Professor Judith Trotman

Clinical Associate Professor
Medicine, Concord Clinical School

Telephone +61 2 9767 5449
Fax +61 2 9767 7650

Map

Biographical details

Associate Professor Judith Trotman, MBChB, FRACP, FRCPA, Spec Cert in Clinical Research (Oncology), is a Senior Staff Specialist and Director, Clinical Research Unit in the Haematology Department, Concord Hospital. With a particular interest in lymphoma care, she has built a broad portfolio of trials across the spectrum of lymphoid malignancies, accessing emerging new therapies for patients from across NSW. Dr Trotman worked as a scholar and clinician in 2009-2010 in the Clinical Research Unit in Lyon, France, within LYSA, the world leading French lymphoma trials collaborative. Her own research demonstrating the predictive power of PET-CT response assessment after first-line therapy in PRIMA, the worlds largest clinical trial in Follicular Lymphoma, has impacted on NCCN guidelines and was recently published in the Journal of Clinical Oncology. Dr Trotman returned to Concord convinced that we have the capacity to build a comprehensive lymphoma research portfolio and deliver World class care, Locally. Committed to both Australian based research and international collaborations she is a member of the ALLG (Australian Leukaemia and Lymphoma Group) Scientific Advisory Committee and the Chair of the Low Grade Lymphoma Committee,and Principal Investigator for two international studies: the UK led, NHMRC funded, Response Adapted Therapy in Hodgkin Lymphoma study (RATHL-HD8), and the French led, REMARC-NHL25 study of Lenalidomide maintenance for older patients with diffuse large B cell lymphoma. She is also the Principal Investigator in the international FOLLCOLL study of PET scanning in Follicular Lymphoma, and of an ALLG world-first study of PET-adapted therapy for patients with relapsed Follicular Lymphoma, and a ovel study of Ibrutinib plus miniRCHOP in very elderly patients with DLBCL. Other national research collaborations include the pharmacokinetics of High Dose Melphalan, the chemotherapy conditioning regimen used before autologous transplantation in Myeloma. She is coinventor of ClinTrial Refer, a smartphone and tablet App that has facilitated increased collaboration in cross-referral and recruitment to clinical trials across 14 research portfolios internationally. She has published extensively in leading haematology journals including Blood, Journal of Clinical Oncology and The Lancet Haematology. Awarded Best Lecturer Year 1 at Concord she has supervised Honours and MD student theses

Research interests

Lymphoproliferative diseases.

Teaching and supervision

Since 2003 A/Prof Trotman has been a tutor, lecturer and the coordinator of the Stage I, Haematology Block, in the Sydney Medical Program. This five week program provides Concord medical students with their first full-time exposure to learning in the Hospital environment. The shared commitment by her and her Concord Haematology colleagues to this program is evidenced by excellent student feedback and performance in RFAs. She is also extensively involved in post graduate teaching for both RACP and RCPA trainees. For 10 years she has been an invited lecturer in haematologic malignancies at the Aljessal/RPAH course for basic physician trainees.

International links

France

(Hospices Civils de Lyon/Université de Lyon, Pierre-Bénite, France) PET and Lymphoma collaboration

Italy

(Oncologia Medica II Università di Modena e Reggio Emilia COM - Centro Oncologico Modenese Via del Pozzo 71 41124 Modena ) Lymphoma collaboration

United Kingdom

(Sally F Barrington Reader in Nuclear Medicine PET Imaging Centre at St Thomas' Lambeth Palace Road London SE1 7EH ) Collaboration in PET in Lymphoma projects

United Kingdom

(University of Southhampton) Hodgkin Lymphoma collaboration with the UKNCRI

Selected grants

2006

  • Using melphalan blood concentrations to reduce toxicity and improve transplant outcome in adult myel; Trotman J, Nath C, Shaw P, Kerridge I; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Johnson, P., Federico, M., Kirkwood, A., Fossa, A., Berkahn, L., Carella, A., D'Amore, F., Enblad, G., Franceschetto, A., Fulham, M., Trotman, J., et al (2016). Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. The New England Journal of Medicine, 374(25), 2419-2429. [More Information]
  • Barrington, S., Kirkwood, A., Franceschetto, A., Fulham, M., Roberts, T., Almquist, H., Brun, E., Hjorthaug, K., Viney, Z., Pike, L., Trotman, J., et al (2016). PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood, 127(12), 1531-1538. [More Information]
  • Millar, A., Ellis, M., Mollee, P., Cochrane, T., Fletcher, J., Caudron, A., Webster, B., Trotman, J. (2015). Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with Diffuse Large B Cell Lymphoma: an Australian retrospective analysis. Internal Medicine Journal, 45(11), 1147-1153. [More Information]
  • Moran, N., Webster, B., Lee, K., Trotman, J., Kwan, Y., Napoli, J., Leong, R. (2015). Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease. World Journal of Gastroenterology, 21(19), 6072-6076. [More Information]
  • Luminari, S., Trotman, J. (2015). Positron emission tomography-computed tomography in follicular lymphoma: "One fit for all"? Leukemia and Lymphoma, 56(5), 1191-1192. [More Information]
  • Barrington, S., Mikhaeel, G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2015). Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. Journal of Clinical Oncology, 33(10), 1221-1223. [More Information]
  • Barrington, S., Mikhael, N., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2015). Reply to G. Keramida et al. Journal of Clinical Oncology, 38(34), 4121-4122. [More Information]
  • Yeung, D., Osborn, M., White, D., Braley, J., Herschtal, A., Branford, S., Kornhauser, M., Issa, S., Hiwase, D., Hertzberg, M., Trotman, J., Taper, J., et al (2015). TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood, 125(6), 915-923. [More Information]
  • Tychyj-Pinel, C., Ricard, F., Fulham, M., Fournier, M., Meignan, M., Lamy, T., Vera, P., Salles, G., Trotman, J. (2014). PET/CT assessment in follicular lymphoma using standardized criteria: Central review in the PRIMA study. European Journal of Nuclear Medicine and Molecular Imaging, 41(3), 408-415. [More Information]
  • Trotman, J., Luminari, S., Boussetta, S., Versari, A., Dupuis, J., Tychyj-Pinel, C., Marcheselli, L., Berriolo-Riedinger, A., Franceschetto, A., Julian, A., et al (2014). Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. The Lancet Haematology, 1(1), e17-e27. [More Information]
  • Karikios, D., Schofield, D., Salkeld, G., Mann, K., Trotman, J., Stockler, M. (2014). Rising cost of anticancer drugs in Australia. Internal Medicine Journal, 44(5), 458-463. [More Information]
  • Barrington, S., Mikhaeel, G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2014). Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology, 32(27), 3048-3058. [More Information]
  • Seymour, J., Trotman, J., Hofman, M. (2013). Evaluating the place of 18-fluoro-2-deoxy-d-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. Leukemia and Lymphoma, 54(10), 2093-2095. [More Information]
  • Gasiorowski, R., Gibson, J., Watson, G., Trotman, J., Larsen, S. (2013). Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement. Pathology, 45(1), 81-83. [More Information]
  • Kiely, B., McCaughan, G., Christodoulou, S., Beale, P., Grimison, P., Trotman, J., Tattersall, M., Stockler, M. (2013). Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Supportive Care in Cancer, 21(2), 369-376. [More Information]
  • Trotman, J., Fournier, M., Lamy, T., Seymour, J., Sonet, A., Janíkova, A., Shpilberg, O., Gyan, E., Tilly, H., Estell, J., Fulham, M., et al (2011). Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. Journal of Clinical Oncology, 29(23), 3194-3200. [More Information]
  • Nath, C., Shaw, P., Trotman, J., Zeng, L., Duffull, S., Hegarty, G., McLachlan, A., Gurney, H., Kerridge, I., Kwan, Y., Joshua, D., et al (2010). Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 69(5), 484-497. [More Information]
  • Michallet, A., Trotman, J., Tychyj-Pinel, C. (2010). Role of early PET in the management of diffuse large B-cell lymphoma. Current Opinion in Oncology, 22(5), 414-8. [More Information]
  • Nath, C., Zeng, L., Eslick, A., Trotman, J., Earl, J. (2008). An isocratic UV HPLC assay for analysis of total and free melphalan concentrations in human plasma. Acta Chromatographicae, 20(3), 383-398. [More Information]
  • Trotman, J., Presgrave, P., Kwan, Y., Tiley, C., Estell, J., Watson, A., O'Brien, T., Peters, D. (2008). Consensus guidelines for 'rainy day' autologous stem cell harvests in New South Wales. Internal Medicine Journal, 38(4), 229-234. [More Information]
  • Chung, T., Lim, W., Sy, R., Cunningham, I., Trotman, J., Kritharides, L. (2008). Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function. Heart, 94(7), 911-918. [More Information]

2016

  • Johnson, P., Federico, M., Kirkwood, A., Fossa, A., Berkahn, L., Carella, A., D'Amore, F., Enblad, G., Franceschetto, A., Fulham, M., Trotman, J., et al (2016). Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. The New England Journal of Medicine, 374(25), 2419-2429. [More Information]
  • Barrington, S., Kirkwood, A., Franceschetto, A., Fulham, M., Roberts, T., Almquist, H., Brun, E., Hjorthaug, K., Viney, Z., Pike, L., Trotman, J., et al (2016). PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood, 127(12), 1531-1538. [More Information]

2015

  • Millar, A., Ellis, M., Mollee, P., Cochrane, T., Fletcher, J., Caudron, A., Webster, B., Trotman, J. (2015). Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with Diffuse Large B Cell Lymphoma: an Australian retrospective analysis. Internal Medicine Journal, 45(11), 1147-1153. [More Information]
  • Moran, N., Webster, B., Lee, K., Trotman, J., Kwan, Y., Napoli, J., Leong, R. (2015). Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease. World Journal of Gastroenterology, 21(19), 6072-6076. [More Information]
  • Luminari, S., Trotman, J. (2015). Positron emission tomography-computed tomography in follicular lymphoma: "One fit for all"? Leukemia and Lymphoma, 56(5), 1191-1192. [More Information]
  • Barrington, S., Mikhaeel, G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2015). Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. Journal of Clinical Oncology, 33(10), 1221-1223. [More Information]
  • Barrington, S., Mikhael, N., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2015). Reply to G. Keramida et al. Journal of Clinical Oncology, 38(34), 4121-4122. [More Information]
  • Yeung, D., Osborn, M., White, D., Braley, J., Herschtal, A., Branford, S., Kornhauser, M., Issa, S., Hiwase, D., Hertzberg, M., Trotman, J., Taper, J., et al (2015). TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood, 125(6), 915-923. [More Information]

2014

  • Tychyj-Pinel, C., Ricard, F., Fulham, M., Fournier, M., Meignan, M., Lamy, T., Vera, P., Salles, G., Trotman, J. (2014). PET/CT assessment in follicular lymphoma using standardized criteria: Central review in the PRIMA study. European Journal of Nuclear Medicine and Molecular Imaging, 41(3), 408-415. [More Information]
  • Trotman, J., Luminari, S., Boussetta, S., Versari, A., Dupuis, J., Tychyj-Pinel, C., Marcheselli, L., Berriolo-Riedinger, A., Franceschetto, A., Julian, A., et al (2014). Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. The Lancet Haematology, 1(1), e17-e27. [More Information]
  • Karikios, D., Schofield, D., Salkeld, G., Mann, K., Trotman, J., Stockler, M. (2014). Rising cost of anticancer drugs in Australia. Internal Medicine Journal, 44(5), 458-463. [More Information]
  • Barrington, S., Mikhaeel, G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S., Schwartz, L., Zucca, E., Fisher, R., Trotman, J., et al (2014). Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology, 32(27), 3048-3058. [More Information]

2013

  • Seymour, J., Trotman, J., Hofman, M. (2013). Evaluating the place of 18-fluoro-2-deoxy-d-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. Leukemia and Lymphoma, 54(10), 2093-2095. [More Information]
  • Gasiorowski, R., Gibson, J., Watson, G., Trotman, J., Larsen, S. (2013). Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement. Pathology, 45(1), 81-83. [More Information]
  • Kiely, B., McCaughan, G., Christodoulou, S., Beale, P., Grimison, P., Trotman, J., Tattersall, M., Stockler, M. (2013). Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Supportive Care in Cancer, 21(2), 369-376. [More Information]

2011

  • Trotman, J., Fournier, M., Lamy, T., Seymour, J., Sonet, A., Janíkova, A., Shpilberg, O., Gyan, E., Tilly, H., Estell, J., Fulham, M., et al (2011). Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. Journal of Clinical Oncology, 29(23), 3194-3200. [More Information]

2010

  • Nath, C., Shaw, P., Trotman, J., Zeng, L., Duffull, S., Hegarty, G., McLachlan, A., Gurney, H., Kerridge, I., Kwan, Y., Joshua, D., et al (2010). Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 69(5), 484-497. [More Information]
  • Michallet, A., Trotman, J., Tychyj-Pinel, C. (2010). Role of early PET in the management of diffuse large B-cell lymphoma. Current Opinion in Oncology, 22(5), 414-8. [More Information]

2008

  • Nath, C., Zeng, L., Eslick, A., Trotman, J., Earl, J. (2008). An isocratic UV HPLC assay for analysis of total and free melphalan concentrations in human plasma. Acta Chromatographicae, 20(3), 383-398. [More Information]
  • Trotman, J., Presgrave, P., Kwan, Y., Tiley, C., Estell, J., Watson, A., O'Brien, T., Peters, D. (2008). Consensus guidelines for 'rainy day' autologous stem cell harvests in New South Wales. Internal Medicine Journal, 38(4), 229-234. [More Information]
  • Chung, T., Lim, W., Sy, R., Cunningham, I., Trotman, J., Kritharides, L. (2008). Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function. Heart, 94(7), 911-918. [More Information]

To update your profile click here. For support on your academic profile contact .